Loading
A phase 1/2 trial of Precemtabart tocentecan in non-small-cell lung cancer and small-cell lung cancer, run by EMD Serono Research & Development Institute, Inc., active and no longer recruiting.
Study of Anti-CEACAM5 ADC M9140 in Participants With Advanced Solid Tumors (PROCEADE PanTumor) is a phase 1/2 interventional study registered as NCT06710132 by EMD Serono Research & Development Institute, Inc., with 184 participants enrolled, started 2025-01-29 and due to reach its primary completion in 2027-12-23. Interventions recorded: M9140. Conditions listed: Solid Tumors, Gastric Cancer, Non-Small Cell Lung Cancer (NSCLC), Pancreatic Cancer. No results are recorded here; the registry entry is the source.
Shares Merck KGaA (EMD Serono), Pancreatic ductal adenocarcinoma.